Clinical Trials Logo

Clinical Trial Summary

To characterize the PK of deferasirox in pediatric β-thalassemia major patients aged from 2 to less than 6 years old, when administrated with a fixed starting dose of 20 mg/kg/day.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT01724138
Study type Interventional
Source Novartis
Contact
Status Withdrawn
Phase Phase 4
Start date June 2013
Completion date October 2014

See also
  Status Clinical Trial Phase
Completed NCT00390858 - A 4-year Extension Study to Core 1-year Study of Iron Chelation Therapy With Deferasirox in β-thalassemia Major Pediatric Patients With Transfusional Iron Overload. Phase 2
Active, not recruiting NCT01846923 - B Memory Cell Response to Vaccination With the 13-valent Pneumococcal Conjugate Vaccine in Asplenic Individuals Phase 4
Terminated NCT04205435 - β-globin Restored Autologous HSC in β-thalassemia Major Patients Phase 1/Phase 2
Not yet recruiting NCT04592458 - Safety and Efficacy Evaluation of β-globin Restored Autologous Hematopoietic Stem Cells in β-thalassemia Major Patients Phase 1
Completed NCT01745120 - A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in β-Thalassemia Major Participants Phase 1/Phase 2
Recruiting NCT05776173 - Safety and Efficacy of Gene Modified Autologous Hematopoietic Stem Cells to Treat Transfusion-dependent β-thalassemia N/A